[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,110,201
  • Shares Outstanding, K 29,480
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 179 M
  • EBITDA $ 185 M
  • 60-Month Beta 0.50
  • Price/Sales 23.51
  • Price/Cash Flow 42.57
  • Price/Book 7.16

Options Overview Details

View History
  • Implied Volatility 40.68% (-0.01%)
  • Historical Volatility 38.58%
  • IV Percentile 25%
  • IV Rank 25.70%
  • IV High 59.65% on 10/31/25
  • IV Low 34.12% on 05/13/26
  • Expected Move (DTE 17) 24.27 (8.14%)
  • Put/Call Vol Ratio 1.35
  • Today's Volume 40
  • Volume Avg (30-Day) 396
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 3,325
  • Open Int (30-Day) 4,691
  • Expected Range 273.83 to 322.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.81
  • Number of Estimates 4
  • High Estimate $1.98
  • Low Estimate $1.59
  • Prior Year $1.29
  • Growth Rate Est. (year over year) +40.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
251.97 +18.31%
on 05/04/26
319.48 -6.69%
on 05/14/26
+32.06 (+12.05%)
since 05/01/26
3-Month
242.00 +23.18%
on 03/31/26
319.48 -6.69%
on 05/14/26
+22.46 (+8.15%)
since 02/27/26
52-Week
124.00 +140.40%
on 06/03/25
319.48 -6.69%
on 05/14/26
+172.14 (+136.66%)
since 05/30/25

Most Recent Stories

More News
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan  VYJUVEK is the first genetic...

KRYS : 298.10 (-3.54%)
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference...

KRYS : 298.10 (-3.54%)
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK)...

KRYS : 298.10 (-3.54%)
Krystal Biotech Reports Revenue Growth but Reimbursement Talks Still Linger in Key Markets

Barchart Research What to Expect from KRYS Earnings KRYS Generated May 1, 2026 Current Price $266.04 EPS Estimate $$1.45 Consensus Rating Strong Buy Average Move 7.05% Krystal Biotech Reports Revenue Growth...

KRYS : 298.10 (-3.54%)
Krystal Biotech Reports Revenue Growth but Reimbursement Talks Still Linger in Key Markets

Barchart Research What to Expect from KRYS Earnings KRYS Generated May 1, 2026 Current Price $266.04 EPS Estimate $$1.45 Consensus Rating Strong Buy Average Move 7.05% Krystal Biotech Reports Revenue Growth...

KRYS : 298.10 (-3.54%)
Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific...

KRYS : 298.10 (-3.54%)
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May...

KRYS : 298.10 (-3.54%)
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its...

KRYS : 298.10 (-3.54%)
PVLA : 112.59 (-4.96%)
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference...

KRYS : 298.10 (-3.54%)
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment...

KRYS : 298.10 (-3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 316.45
2nd Resistance Point 312.74
1st Resistance Point 305.42
Last Price 298.10
1st Support Level 294.39
2nd Support Level 290.68
3rd Support Level 283.36

See More

52-Week High 319.48
Last Price 298.10
Fibonacci 61.8% 244.81
Fibonacci 50% 221.74
Fibonacci 38.2% 198.67
52-Week Low 124.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.